The complexity after simplicity: How to proceed with renal denervation in hypertension?

European Journal of Preventive Cardiology

Volumn 22, Issue 4, 2015, Pages 412-414

  Blankestijn, Peter J ^a   Alings, Marco ^a,b   Voskuil, Michiel ^a   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AFRICAN AMERICAN; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); ETHNIC GROUP; HUMAN; HYPERTENSION; KIDNEY DENERVATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; ANIMAL; BLOOD STORAGE; CATHETER ABLATION; EVIDENCE BASED MEDICINE; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPATHECTOMY; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESERVATION; CATHETER ABLATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; KIDNEY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84924982438     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314538859     Document Type: Article

References (15)

1. Bhatt DL, Kandzari DE, O'Neill WW, et al. The SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J 2014; 370(15): 1393-1401.
2. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009 ; 373: 1275-1281
3. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomized controlled trial. Lancet. 2010 ; 376: 1903-1909
4. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 ; 35: 528-535
5. Blankestijn PJ, Ritz E. Renal denervation: Potential impact on hypertension in kidney disease?. Nephrol Dial Transplant. 2011 ; 26: 2732-2734
6. Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol. 2012 ; 3: 29-29
7. Vink EE, De Jager RL, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: Pathophysiology and (new) treatment options. Curr Hypertens Rep. 2013 ; 15: 95-101
8. Vink EE, Bots ML, Blankestijn PJ. Renal denervation as therapy for hypertension: Potentials and unanswered questions. Eur J Prev Cardiol. 2013 ; 20: 980-991
9. Beus E, De Jager R, Joles JA, et al. Sympathetic activation in chronic kidney disease: Therapeutic target for renal denervation?. J Hypertens. 2014 ; PubMed PMID: 24805954-24805954
10. Messerli FH, Bangalore S. Renal denervation for resistant hypertension?. N Engl J Med. 2014 ; 370: 1454-1457
11. Verloop WL, Vink EE, Voskuil M, et al. Eligibility for percutaneous renal denervation: The importance of a systematic screening. J Hypertens. 2013 ; 31: 1662-1668
12. Persu A, Jin Y, Baelen M, Vink E, et al. on behalf of the European Network Coordinating research on Renal Denervation (ENCOReD) Consortium. Eligibility for renal denervation: Experience at 11 European Expert Centers. Hypertension. Epub ahead of print 24 March 2014. PubMed PMID: 24664290.
13. Vink EE, Verloop WL, Bost RB, et al. The blood pressure lowering effect of renal denervation is inversely related to kidney function. J Hypertens. 2014 ;:
14. Vink EE, Goldschmeding R, Vink A, et al. Limited destruction of renal nerves after catheter based renal denervation. Results of a human case study. Nephrol Dial Transplant. 2014 ;:
15. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013 ; 31: 766-774